Determination of Regulatory Review Period for Purposes of Patent Extension; COBENFY
Published Date: 2/6/2026
Notice
Summary
The FDA has set the official review period for COBENFY, a human drug, so its patent holder can apply for extra patent time. This affects the drug company and anyone tracking patent protections, with deadlines to challenge dates or diligence claims by April 7 and August 5, 2026. It’s a key step to help the company protect its invention longer, potentially impacting when generic versions can enter the market.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
FDA sets COBENFY review period
FDA determined COBENFY's regulatory review period is 11,751 days total (testing phase 11,384 days and approval phase 367 days). FDA lists the IND effective date as July 27, 1992, the NDA initial submission as September 26, 2023, and the NDA approval as September 26, 2024; the applicant seeks 1,124 or 1,191 days of patent term extension and the USPTO will apply statutory limits when calculating the actual extension.
Deadlines to challenge dates or diligence
Anyone who believes the published dates are incorrect may ask FDA for a redetermination by April 7, 2026, and any interested person may petition FDA about whether the applicant acted with due diligence by August 5, 2026. Petitions and comments must follow the submission instructions in the notice (including using https://www.regulations.gov or written submissions).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
2026-16944, Gardenia Blue Interest Group; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Gardenia Blue Interest Group (GBIG or petitioner), c/o Exponent, Inc., proposing that we amend our color additive regulations to expand the safe use of gardenia (genipin) blue in various foods at levels consistent with good manufacturing practice. The petition also proposes to lower the specification for arsenic in gardenia (genipin) blue.
Previous / Next Documents
Previous: 2026-02387, Determination of Regulatory Review Period for Purposes of Patent Extension; BEQVEZ
The FDA has set the official review period for BEQVEZ, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind BEQVEZ and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s effort during review, you have until early August 2026 to speak up—no money changes hands now, but this could impact how long the patent lasts.
Next: 2026-02390, Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company
Some folks want to buy shares in banks or bank companies, and the Federal Reserve is checking their applications to make sure everything’s on the up and up. If you want to share your thoughts, you’ve got until February 23, 2026, to speak up. This process helps keep banks safe and sound while letting new owners step in smoothly.